Michael V Seiden

Michael V Seiden

UNVERIFIED PROFILE

Are you Michael V Seiden?   Register this Author

Register author
Michael V Seiden

Michael V Seiden

Publications by authors named "Michael V Seiden"

Are you Michael V Seiden?   Register this Author

65Publications

849Reads

15Profile Views

Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value.

Am J Manag Care 2017 Feb;23(2 Spec No.):SP69-SP77

10101 Woodloch Forest Dr, The Woodlands, TX 77380. E-mail:

View Article

Download full-text PDF

Source
February 2017

The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites.

Gynecol Oncol 2013 Feb 15;128(2):187-90. Epub 2012 Nov 15.

Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL 60611,USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2012.11.013DOI Listing
February 2013

Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location.

J Natl Compr Canc Netw 2012 Sep;10(9):1076-80

From Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2012.0113DOI Listing
September 2012

Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.

Gynecol Oncol 2010 Feb 18;116(2):168-72. Epub 2009 Nov 18.

Dana-Farber/Harvard Cancer Center, representing members of the DF/HCC Gynecologic Oncology Research Group at Massachusetts General Hospital, and Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2009.10.075DOI Listing
February 2010

CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.

Stem Cells 2009 Dec;27(12):2875-83

Vincent Center for Reproductive Biology, Vincent Obstetrics and Gynecology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/stem.236DOI Listing
December 2009

Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.

J Allergy Clin Immunol 2009 Jun;123(6):1262-7.e1

Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2009.02.042DOI Listing
June 2009

Progress in gynecologic cancer.

Authors:
Michael V Seiden

Semin Oncol 2009 Apr;36(2):90

Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2008.12.010DOI Listing
April 2009

CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells.

Cancer Chemother Pharmacol 2009 Mar 28;63(4):681-9. Epub 2008 Jun 28.

Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-008-0785-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875930PMC
March 2009

Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model.

Mol Pharm 2008 Jul-Aug;5(4):516-26. Epub 2008 Jul 11.

Department of Pharmaceutical Sciences, Northeastern University, Department of Orthopedic Surgery, Massachusetts General Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/mp800030kDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646668PMC
October 2008

Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles.

Clin Cancer Res 2008 May;14(10):3193-203

Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-4973DOI Listing
May 2008

Mechanisms of Cables 1 gene inactivation in human ovarian cancer development.

Cancer Biol Ther 2008 Feb 15;7(2):180-88. Epub 2007 Nov 15.

Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, Massachussetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.7.2.5253DOI Listing
February 2008

Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells.

Cell Cycle 2008 Jan 24;7(2):242-9. Epub 2007 Oct 24.

Vincent Center for Reproductive Biology, Vincent Obstetrics and Gynecology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.7.2.5207DOI Listing
January 2008

8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.

Mol Pharmacol 2007 Nov 3;72(5):1137-45. Epub 2007 Aug 3.

Department of Hematology/Oncology, Massachusetts General Hospital, 100 Blossom St. Jackson 1008, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://molpharm.aspetjournals.org/cgi/doi/10.1124/mol.107.03
Publisher Site
http://dx.doi.org/10.1124/mol.107.038117DOI Listing
November 2007

Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer.

Int J Cancer 2007 Oct;121(8):1830-8

Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.22886DOI Listing
October 2007

Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.

Cancer Res 2007 May;67(10):4843-50

Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://igert.neu.edu/research/publications/dbuploads/article
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-06-1648DOI Listing
May 2007

Case records of the Massachusetts General Hospital. Case 13-2007. A 46-year-old woman with gynecologic and intestinal cancers.

N Engl J Med 2007 Apr;356(17):1760-9

Department of Medicine, Massachusetts General Hospital, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMcpc079007DOI Listing
April 2007

Pooling of case specimens to create standard serum sets for screening cancer biomarkers.

Cancer Epidemiol Biomarkers Prev 2007 Feb;16(2):334-41

Biostatistics Center, Massachusetts General Hospital, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-06-0681DOI Listing
February 2007

Demographic, risk factor, and knowledge differences between Latinas and non-Latinas referred to colposcopy.

Gynecol Oncol 2007 Jan 1;104(1):70-6. Epub 2006 Sep 1.

Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2006.07.008DOI Listing
January 2007

Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.

Clin Cancer Res 2007 Jan;13(2 Pt 1):584-90

Beth Israel Deaconess Medical Center, and Harvard Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0964DOI Listing
January 2007

Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma.

Gynecol Oncol 2006 Nov 12;103(2):570-4. Epub 2006 Jun 12.

Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2006.04.011DOI Listing
November 2006

Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.

Proc Natl Acad Sci U S A 2006 Nov 6;103(46):17426-31. Epub 2006 Nov 6.

Pediatric Surgical Research Laboratories, Department of Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://www.pnas.org/cgi/doi/10.1073/pnas.0607959103
Publisher Site
http://dx.doi.org/10.1073/pnas.0607959103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1859945PMC
November 2006

SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.

Clin Cancer Res 2006 Nov;12(22):6844-52

Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, and Chemical Biology Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-1330DOI Listing
November 2006

Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.

Clin Cancer Res 2006 Sep;12(17):5055-63

Division of Hematology/Oncology, Department of Pathology, and Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0861DOI Listing
September 2006

Reclassification of a tubal leiomyosarcoma as an eGIST by molecular evaluation of c-KIT.

Gynecol Oncol 2006 May 24;101(2):363-6. Epub 2006 Jan 24.

Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S009082580501088
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2005.12.022DOI Listing
May 2006

A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.

Gynecol Oncol 2006 Apr 2;101(1):55-61. Epub 2005 Nov 2.

Gynecologic Oncology Research Program at Dana Farber/Partners Cancer Care Program, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2005.09.036DOI Listing
April 2006

Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway.

Mol Cancer Ther 2006 Apr;5(4):952-61

Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-05-0493DOI Listing
April 2006

GBP1 overexpression is associated with a paclitaxel resistance phenotype.

Cancer Chemother Pharmacol 2006 Jan 5;57(1):25-33. Epub 2005 Nov 5.

Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-005-0026-3DOI Listing
January 2006

Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.

Gynecol Oncol 2006 Jan 19;100(1):205-9. Epub 2005 Sep 19.

Division of Medical Oncology, Massachusetts General Hospital, Cox 640, 100 Blossom Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2005.08.006DOI Listing
January 2006

Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.

J Pain Symptom Manage 2005 Dec;30(6):563-9

Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpainsymman.2005.05.018DOI Listing
December 2005

Topotecan: weighing in when there are many options.

Oncologist 2005 Oct;10(9):698-700

Department of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.10-9-698DOI Listing
October 2005

Laughter: the best medicine?

Oncologist 2005 Sep;10(8):651-60

Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, 02114-2617, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.10-8-651DOI Listing
September 2005

Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors.

Cancer 2005 May;103(9):1925-31

Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.21002DOI Listing
May 2005

Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.

Cancer Chemother Pharmacol 2005 Mar 24;55(3):277-85. Epub 2004 Nov 24.

Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-004-0878-yDOI Listing
March 2005

Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.

Curr Treat Options Oncol 2005 Mar;6(2):103-14

Department of Oncology, Massachusetts General Hospital, Cox 6, 100 Blossom St., Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
March 2005

Cone damage in patients receiving high-dose irofulven treatment.

Arch Ophthalmol 2005 Jan;123(1):29-34

Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44124, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archopht.123.1.29DOI Listing
January 2005

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.

Gynecol Oncol 2004 Dec;95(3):624-31

Dana-Farber/Harvard Cancer Center Program in Gynecologic Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2004.08.028DOI Listing
December 2004

MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines.

Gene 2004 Sep;340(1):53-9

Department of Hematology/Oncology, Massachusetts General Hospital, Jackson 1029, 70 Blossom Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gene.2004.06.013DOI Listing
September 2004

Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.

Mol Cancer Ther 2004 Jul;3(7):833-8

Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/content/3/7/833.full.pdf
Web Search
July 2004

A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.

Gynecol Oncol 2004 Apr;93(1):229-32

The Division of Medical Oncology, New York University, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2003.12.037DOI Listing
April 2004

Phase II trial of anastrozole in women with asymptomatic müllerian cancer.

Gynecol Oncol 2003 Dec;91(3):596-602

Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2003.08.021DOI Listing
December 2003

Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.

Clin Cancer Res 2003 Nov;9(14):5178-86

Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
November 2003

Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia--a pilot study.

Gynecol Obstet Invest 2003 ;55(1):25-31

Divisions of Gynecologic Oncology and Hematology Oncology, Massachusetts General Hospital, Boston, Mass, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000068953DOI Listing
July 2003

Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines.

Clin Cancer Res 2003 Jul;9(7):2778-85

Department of Hematology/Oncology Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
July 2003

Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.

Cancer Res 2003 May;63(9):2200-5

Division of Hematology/Oncology, Massachusetts General Hospital Boston 02114, USA.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/canres/63/9/2200.f
Web Search
May 2003

beta tubulin mutations are rare in human ovarian carcinoma.

Anticancer Res 2003 Jan-Feb;23(1B):681-6

Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
April 2003

A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.

Clin Cancer Res 2002 Mar;8(3):691-7

Department of Medicine, Massachusetts General Hospital, Boston 02114, USA.

View Article

Download full-text PDF

Source
March 2002

Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center.

Cancer 2002 Jan;94(2):305-13

Division of Hematology/Oncology, Massachusetts General Hospital, Boston 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.10223DOI Listing
January 2002

cDNA Technologies and their application to drug resistance research: power, potential and problems.

Drug Resist Updat 2000 Oct;3(5):277-282

Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1054/drup.2000.0163DOI Listing
October 2000